Literature DB >> 30861564

Quality of Life but not Cognition is Impacted by Radiotherapy in Patients with Non-Functioning Pituitary Adenoma.

Genevieve Crouzeix1, Rémy Morello2, Juliette Thariat3, Julia Morera4, Michael Joubert4,5, Yves Reznik4,5.   

Abstract

Non-functioning pituitary adenomas (NFPA) are benign neoplasms that are first treated by surgery and secondary radiation therapy in case of residual tumor or regrowth. The consequences of surgery and radiotherapy are still debated. The objective of the work was to assess the impact of surgery, radiotherapy (RT) and pituitary deficiencies on long term health-related quality of life (QoL) and cognitive function among NFPA patients. Forty-six NFPA patients were studied after 9.6±7.5 years follow-up using: i) the MoCA questionnaire to detect mild cognitive disabilities, ii) the McNair and Kahn scale to assess perceived cognitive impairment, iii) the HADS questionnaire to score anxiety and depression, and iv) the SF-36 and QLS-H questionnaires to assess QoL. All NFPA patients had surgery and 54% patients had radiation therapy (RT+). The MoCA score was abnormal in 41% NFPA patients. Neither the type of surgery nor radiotherapy influenced the prevalence of cognitive disabilities. The depression score was higher in RT+than RT- patients. Overall, no alteration in SF-36 and QLS-H QoL scales were observed in NFPA patients when compared with the French reference population. Among NFPA patients, mental composite score, general health and vitality scores were altered in RT+compared to RT- patients. The presence of multiple pituitary axis deficiencies worsened general health and vitality scale scoring. Consistent follow-up had a beneficial impact on psycho-emotional dimensions of health. Surgery and radiotherapy had no adverse effects on cognitive functions, however, QoL was altered in RT+patients. These latter alterations may be partly related to pituitary hormone deficiencies. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2019        PMID: 30861564     DOI: 10.1055/a-0850-9448

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  2 in total

1.  SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements.

Authors:  Merel van der Meulen; Amir H Zamanipoor Najafabadi; Daniel J Lobatto; Cornelie D Andela; Thea P M Vliet Vlieland; Alberto M Pereira; Wouter R van Furth; Nienke R Biermasz
Journal:  Endocrine       Date:  2020-06-19       Impact factor: 3.633

2.  The fatigue, sleep and physical activity in postoperative patients with pituitary adenoma: what we can do.

Authors:  Xin Zhao; Ting Wang; Guixiao Sheng; Yanyao Tang; Meifen Shen; Jianping Yang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.